milgamma® protect – Your solution for nerve damage caused by diabetes-related vitamin B1 deficiency

milgamma<sup>®</sup> protekt

People with diabetes often may become aware of their nerve damage through altered sensations like tingling, burning, numbness and pain in the feet. This nerve damage (neuropathies) is often caused by a vitamin B1 deficiency. What starts with slight sensations like tingling or burning, can lead to significant pain and numbness. When heat, cold, pressure and pain are no longer felt, problems can be expected. If foot injuries are not perceived, they often remain unrecognized and untreated. Various consequences could follow leading up to the ‘diabetic foot syndrome’.

milgamma® protekt can contribute to successfully counteracting these nerve disorders. It contains the active substance benfotiamine, a precursor of vitamin B1, that effectively compensates for the vitamin B1 deficiency which is common among diabetic patients.

milgamma® protekt compensates the nerve damaging vitamin B1 deficiency and relieves the symptoms of tingling, burning and numbness in the feet. With only 1 tablet per day.

  • Application areas

    Treatment of neuropathies and cardiovascular disorders that are caused by vitamin B1 deficiency. Proven therapeutic indications for mono-preparations are exclusively treatment or prophylaxis of clinical vitamin B1 deficiencies, that cannot be corrected through a healthy diet.

  • Drug and composition

    One tablet contains benfotiamine (lipid-soluble vitamin B1 derivative) 300 mg.


    For other ingredients refer to the Direction for use.
  • Dosage and method of administration

    The tablets are best to be taken by swallowing without chewing with sufficient fluid.

    The duration of administration is determined by the therapeutic response.

    For the treatment of neuropathies, milgamma® protekt tablets should be taken initially over a period of at least 3 weeks.

    Afterwards maintenance treatment in accordance with therapeutic response. If no efficacy or a too slight efficacy is recognizable after 4 weeks, the treatment of the complaints should be examined.

  • Package Sizes
    • 30 Film-coated Tablets - PZN 01528157
    • 60 Film-coated Tablets - PZN 17414438
    • 90 Film-coated Tablets - PZN 01529731

  • Required text

    milgamma® protekt. Active substance: Benfotiamine. Therapeutic indications: Treatment of neuropathies and cardiovascular disorders that are caused by vitamin B1 deficiency. If you have any questions about risks and side effects, please read the patient information leaflet and ask your doctor or pharmacist. WÖRWAG Pharma GmbH & Co. KG, 71034 Böblingen

  • Downloads